Correspondence

Advice on scheduling of cannabis-derived medicinal products

Advice from the Advisory Council on the Misuse of Drugs (ACMD) to the Home Office about the scheduling of cannabis-derived medicinal products.

• From: Advisory Council on the Misuse of Drugs
• Published: 19 July 2018

Documents

Scheduling of cannabis-derived medicinal products: ACMD response

PDF, 388 KB, 4 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

Letter from the ACMD chair, Dr Owen Bowden-Jones, to the Home Secretary Sajid Javid, responding to the commission to consider the appropriate scheduling of cannabis-derived medicinal products.

This follows part 1 of the review conducted by the Chief Medical Officer, which evaluated existing research into the therapeutic and medicinal benefits of cannabis-derived medicinal products.

Published 19 July 2018